Schütz A, Härtig W, Wobus M, Grosche J, Wittekind Ch, Aust G
Institute of Pathology, University of Leipzig, Liebigstrasse 26, 04103, Leipzig, Germany.
Virchows Arch. 2005 Apr;446(4):421-9. doi: 10.1007/s00428-004-1193-z. Epub 2005 Mar 9.
ADAM15, a member of the ADAM (a disintegrin and metalloprotease) family, is a membrane protein containing both protease and adhesion domains and may, thus, be involved in tumor invasion and metastasis. The aim of this study was to analyze the expression of ADAM15 and its potential ligand, integrin alpha(v)beta3 (CD51/CD61), in lung carcinoma cell lines and tissues. Most small cell lung carcinomas (SCLCs) and non-SCLC cell lines were ADAM15, alpha(v) and beta3 integrin mRNA positive. Half of the cell lines expressed ADAM15, and three expressed the alpha(v)beta3 heterodimer at the cell surface as shown using flow cytometry. Paraffin sections of pulmonary epithelial tumors, including SCLCs (n=26), squamous cell cancer (SCCs, n=27) and adenocarcinomas (ACs, n=17) were stained with antibodies to the ectosolic and cytosolic domain of ADAM15 and alpha(v)beta3 integrin complex. The results were scored (0-12, according to Remmele's score). Normal epithelial cells of the lung were negative or slightly positive for ADAM15 (score<2). The score was always significantly higher for tumor cells. ACs showed the strongest staining (tumor center; ADAM15ecto; mean+/-SEM; 5.47+/-1.04), whereas SCLCs only showed weak ADAM15 expression (2.67+/-0.42; SCCs: 3.62+/-0.62). Frequently, significantly stronger ADAM15 expression has been shown in tumor cells located at the front of invasion compared with those within solid formations. Overall analysis of all tumor specimens and each tumor type revealed no significant correlation between tumor stage or degree of differentiation and ADAM15 ectosolic or cytosolic domain expression in tumor cells. Both molecules are often co-localized in the same tumor cells in ADAM15- and alpha(v)beta3 integrin-positive carcinomas. In summary, lung carcinoma cell lines and tissues were frequently ADAM15 positive.
ADAM15是ADAM(一种去整合素和金属蛋白酶)家族的成员,是一种同时含有蛋白酶结构域和黏附结构域的膜蛋白,因此可能参与肿瘤侵袭和转移。本研究的目的是分析ADAM15及其潜在配体整合素α(v)β3(CD51/CD61)在肺癌细胞系和组织中的表达情况。大多数小细胞肺癌(SCLC)和非小细胞肺癌细胞系ADAM15、α(v)和β3整合素mRNA呈阳性。一半的细胞系表达ADAM15,流式细胞术检测显示有三个细胞系在细胞表面表达α(v)β3异二聚体。对包括SCLC(n = 26)、鳞状细胞癌(SCC,n = 27)和腺癌(AC,n = 17)在内的肺上皮肿瘤石蜡切片,用针对ADAM15胞外和胞质结构域以及α(v)β3整合素复合物的抗体进行染色。根据Remmele评分标准(0 - 12分)对结果进行评分。肺正常上皮细胞ADAM15呈阴性或弱阳性(评分<2)。肿瘤细胞的评分总是显著更高。腺癌显示出最强的染色(肿瘤中心;ADAM15胞外;平均值±标准误;5.47±1.04),而小细胞肺癌仅显示出较弱的ADAM15表达(2.67±0.42;鳞状细胞癌:3.62±0.62)。与实体瘤内部的肿瘤细胞相比,侵袭前沿的肿瘤细胞中ADAM15表达通常显著更强。对所有肿瘤标本和每种肿瘤类型的综合分析显示,肿瘤分期或分化程度与肿瘤细胞中ADAM15胞外或胞质结构域表达之间无显著相关性。在ADAM15和α(v)β3整合素阳性的癌中,这两种分子常共定位于同一肿瘤细胞中。总之,肺癌细胞系和组织中ADAM15常呈阳性。